Overview

This trial is active, not recruiting.

Condition abdominal aortic aneurysms (aaa)
Treatment aptus endovascular aaa repair system
Phase phase 2
Sponsor Aptus Endosystems
Start date September 2007
End date January 2014
Trial size 155 participants
Trial identifier NCT00507559, 2007-01

Summary

A prospective, non-randomized, multi-center clinical study to evaluate the safety and effectiveness of the Aptus Endovascular AAA Repair System compared to an open surgical repair historical control group in the treatment of abdominal aortic aneurysms.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
Safety: MAE Effectiveness: Composite Success Rate
time frame: Safety 30 days and Effectiveness 1 year

Secondary Outcomes

Measure
Safety: all AEs and SAEs Effectiveness: clinical utility and device performance
time frame: 1 year

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: - Infrarenal AAA with a maximum diameter ≥ 4.5 cm. - Infrarenal AAA with at least 12 mm length of non-aneurysmal proximal neck. - Infrarenal AAA with a proximal neck internal diameter between 19-29 mm. - Infrarenal AAA with an internal diameter at the aortic bifurcation ≥ 18 mm. - Infrarenal AAA with an angle of ≤ 60° relative to the long axis of the aneurysm. - Bilateral iliac artery distal fixation sites ≥ 10 mm in length. - Bilateral iliac arteries with an internal diameter between 9 and 20 mm. - Bilateral femoral/iliac arteries with morphology compatible with standard vascular access techniques and vessel size must accommodate a 16F (5.3 mm) or 18F (6.0 mm) delivery system. Exclusion Criteria: - Myocardial infarction within past 10 weeks. - Active systemic infection. - Ruptured or leaking AAA. - Mycotic or inflammatory AAA. - Genetic connective tissue disorders (e.g., Marfans or Ehlers-Danlos Syndromes). - Concomitant TAA or thoracoabdominal aortic aneurysms. - Requires emergent AAA surgery. - Previous AAA repair. - Patients with a body habitus that would prevent imaging required by the study. - Patient has significant comorbid conditions that pose undue risk of general anesthesia or endovascular surgery. - Patient requires additional planned major procedure at the time of AAA repair or within 30 days before or after AAA repair. - Dialysis dependent renal failure or creatinine > 2.5 mg/dL. - Allergy to or intolerance of radiopaque contrast agents. - Patients with a known sensitivity or allergy to implant materials. - Patients who cannot discontinue oral anticoagulation or antiplatelet therapy at the time of the study procedure. - Patients with history of bleeding diathesis or hypercoagulable condition. - Patients with thrombus, calcification, and/or plaque ≥ 2mm in thickness and/or ≥ 50% (180°) continuous coverage of the vessel circumference in the intended seal zone. - Patients with irregular shaped calcification and/or plaque that may compromise the fixation and sealing at the proximal or distal implantation sites.

Additional Information

Official title The Pivotal Study of the Aptus Endovascular AAA Repair System
Principal investigator Ronald M Fairman, M.D
Trial information was received from ClinicalTrials.gov and was last updated in February 2012.
Information provided to ClinicalTrials.gov by Aptus Endosystems.